Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study

Yuqi Wang, Jiayi Liu, Jiaxin Wang, Xiaoli Liu, Jingxin Zhang, Dawei Chen · 2026

Read Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study by Yuqi Wang, Jiayi Liu, Jiaxin Wang, Xiaoli Liu, Jingxin Zhang, Dawei Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13199695.txt.

Description

Yuqi Wang and colleagues compared first-line chemotherapy blends for spread pancreatic cancer in a 2026 records study. Three blends are all guideline-backed, yet which works best in daily practice was unsettled. The team reviewed patients treated at one center over about eighteen months.

They covered 215 patients across three regimens. NALIRIFOX, a four-drug blend, showed the best profile: longest time before growth, at a median of nine months, plus the highest response and disease-control rates. Overall survival had not yet split clearly between groups. Adjusted math still favored NALIRIFOX and a second blend over the third. Side effects were mostly mild, with no treatment deaths. Alcohol use independently tied to poorer survival.

Catalog record

CREATORYuqi Wang, Jiayi Liu, Jiaxin Wang, Xiaoli Liu, Jingxin Zhang, Dawei Chen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13199695

Browse the full library · About the Tower of Babel